Trials / Completed
CompletedNCT01151540
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 4 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rufinamide | The target dosage is approximately 45 mg/kg/day, taken orally twice a day. |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2010-06-28
- Last updated
- 2019-03-11
- Results posted
- 2019-03-11
Locations
23 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01151540. Inclusion in this directory is not an endorsement.